Vasoactive intestinal peptide as a healing mediator in Crohn's disease.
The vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide (VIP/PACAP) system is considered as a paradigm for the use of a neuroendocrine-immune mediator in therapy. We review the role of VIP in 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis as a murine model of Crohn's disease. VIP treatment led to the recovery of clinical factors, the amelioration of parameters related to the recruitment and traffic of cell populations, and the balance of inflammatory mediators derived from granulocytes, antigen-presenting cells and T lymphocytes including Th1, Th2 and Th17. Finally, the most recent data validate its therapeutic role through the modulation of TLR2 and 4 receptors.
Arranz
A
A
Departamento de Biología Celular, Facultad de Biología, Universidad Complutense de Madrid, Madrid, Spain.
Abad
C
C
Juarranz
Y
Y
Leceta
J
J
Martinez
C
C
Gomariz
R P
RP
D000818:Animals; D000938:Antigen-Presenting Cells / Q000187:drug effects / Q000276:immunology; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D004195:Disease Models, Animal; D006098:Granulocytes / Q000187:drug effects / Q000276:immunology; D006801:Humans; D051379:Mice; D015213:Neuroimmunomodulation / Q000187:drug effects / Q000276:immunology; D009490:Neurosecretory Systems / Q000187:drug effects* / Q000276:immunology / Q000503:physiopathology; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000276:immunology* / Q000378:metabolism; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology* / Q000627:therapeutic use
D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D014660:Vasoactive Intestinal Peptide